Balyasny Asset Management
MAZE

Balyasny Asset Management’s Maze Therapeutics MAZE Stock Holding History

Balyasny Asset Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602K Sell
20,190
-440,961
-96% -$11.6M ﹤0.01% 2445
2026
Q1 		$13.8M Buy
461,151
+261,939
+131% +$11.6M 0.02% 867
2025
Q4 		$8.25M Sell
199,212
-234,513
-54% -$8.06M 0.01% 1120
2025
Q3 		$11.2M Buy
+433,725
New +$7.32M 0.01% 991

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Balyasny Asset Management's MAZE Position: Q2 2026 in Review

Balyasny Asset Management reduced its Maze Therapeutics (MAZE) stake by 96% in Q2 2026, selling an estimated $11.6M and leaving 20,190 shares worth $602K. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Balyasny Asset Management first reported a position in MAZE in Q3 2025 and has held it in 4 quarters since. The position peaked at $13.8M in Q1 2026. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Balyasny Asset Management held 20,190 shares of Maze Therapeutics worth $602K as of Q2 2026.
  • Balyasny Asset Management sold 440,961 Maze Therapeutics shares in Q2 2026, an estimated $11.6M.
  • Maze Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2445 holding.
  • Balyasny Asset Management first reported a position in Maze Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Balyasny Asset Management's Maze Therapeutics position peaked at $13.8M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.